91ֱ��

All publications

Journal articles

• Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) . Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
• Griffin J, Down J, Quayle LA, Heath PR, Gibb EA, Davicioni E, Liu Y, Zhao X, Swain J, Wang D , Hussain S et al (2024) . The Journal of Pathology: Clinical Research, 10(2).
• Zhou J, Down JM, George CN, Murphy J, Lefley DV, Tulotta C, Alsharif MA, Leach M & Ottewell PD (2022) . Cancers, 14(19).
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al (2021) . Journal of Bone Oncology, 31.
• Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) . Journal for ImmunoTherapy of Cancer, 9(3).
• Crawford LJ, Campbell DC, Morgan JJ, Lawson MA, Down JM, Chauhan D, McAvera RM, Morris TC, Hamilton C, Krishnan A , Rajalingam K et al (2020) . Oncogene.
• Green AC, Lath D, Hudson K, Walkley B, Down JM, Owen R, Evans HR, Paton‐Hough J, Reilly GC, Lawson MA & Chantry AD (2019) . Journal of Bone and Mineral Research, 34(12), 2311-2326.
• Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) . Blood, 132(Supplement 1), 3213-3213.
• Paton-Hough J, Tazzyman S, Evans H, Lath D, Down JM, Green AC, Snowden JA, Chantry AD & Lawson MA (2018) . Journal of Bone and Mineral Research.
• Lath DL, Buckle CH, Evans HR, Fisher M, Down JM, Lawson MA & Chantry AD (2018) . PLoS One, 13(6).
• (2018) . Endocrinology, 159(4), 1762-1762.
• Chai RC, McDonald MM, Terry RL, Kovačić N, Down JM, Pettitt JA, Mohanty ST, Shah S, Haffari G, Xu J , Gillespie MT et al (2017) . Oncotarget, 8, 68047-68058.
• Chinnaiya K, Lawson MA, Thomas S, Haider M-T, Down J, Chantry AD, Hughes D, Green A, Sayers JR, Snowden JA & Zeidler MP (2017) . Haematologica, 102, e336-e339.
• Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA , Neil Dear T et al (2015) . Nature Communications, 6(1), ---.
• Bassett JHD, van der Spek A, Logan JG, Gogakos A, Bagchi-Chakraborty J, Murphy E, van Zeijl C, Down J, Croucher PI, Boyde A , Boelen A et al (2015) . Endocrinology, 156(9), 3098-3113.
• Reeves KJ, Hurrell JE, Cecchini M, van der Pluijm G, Down JM, Eaton CL, Hamdy F, Clement-Lacroix P & Brown NJ (2015) . International Journal of Cancer, 136(7), 1731-1740.
• Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B , McKenna CE et al (2015) . Cancer Discovery, 5(1), 35-42.
• Mathew G, Mitchell A, Down JM, Jacobs LA, Hamdy FC, Eaton C, Rosario DJ, Cross SS & Winder SJ (2013) . Scientific Reports, 3(1).
• Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, Pesce G, Phillips JT, Yen OS, Thalmann GN , Wright PC et al (2012) iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer.. PLoS ONE.
• van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG , Pelger RCM et al (2010) . Cancer Research, 70(12), 5163-5173.
• Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F & Thalman G (2010) . The Prostate, 70(8), 875-882.
• Glen A, Evans CA, Gan CS, Cross SS, Hamdy FC, Gibbins J, Lippitt J, Eaton CL, Noirel J, Wright PC & Rehman I (2010) . The Prostate, n/a-n/a.
• Cross SS, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian SP, Reed MW, Eaton C, Catto JW, Hamdy F & Winder SJ (2008) . Histopathology, 53(5), 561-566.
• Waterman EA, Cross NA, Lippitt JM, Cross SS, Rehman I, Holen I, Hamdy FC & Eaton CL (2007) . International Journal of Cancer, 121(9), 1958-1966.
• Cross SS (2006) . Journal of Clinical Pathology, 59(7), 716-720.
• Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) . International Journal of Cancer, 118(8), 1901-1908.
• Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) . Breast Cancer Research and Treatment, 92(3), 207-215.
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ & Carding SR (2003) . Immunity, 19(6), 849-861.
• Shipman CM, Vanderkerken K, De Raeve H, Perry M, Hijzen A, Lippitt J, Green J, Van Marck E, Van Camp B & Croucher PI (2002) Zoledronic acid prevents the development of myeloma bone disease and increases survival. JOURNAL OF BONE AND MINERAL RESEARCH, 17(7), 1328-1328.
• Croucher P, De Raeve H, Perry M, Hijzen A, Shipman C, Lippitt J, Green J, Van Marck E, Van Camp B & Vanderkerken K (2002) Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. BONE, 30(3), 39S-39S.
• Shipman CM, Lippitt JM & Croucher PI (2002) Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?. BONE, 30(3), 32S-32S.
• Ashcroft AJ, Lippitt JM, Perry MJ, Rollinson SJ, Croucher PI, Carding SR & Morgan GJ (2001) Interleukin 2 deficiency induces bone destruction associated with dysregulation of the rank/rank ligand/osteoprotegerin system. Blood, 98(11 PART I).
• Croucher PI, Hijzen A, Shipman CM, Perry M, Lippitt J, Green J, Van Camp B & Vanderkerken K (2001) Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood, 98(11 PART I).
• Croucher PI, Shipman CM, Perry M, Lippitt J, Asosingh K, van Beek EJR, Van Camp B, Russell RGG, Dunstan C & Vanderkerken K (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. BONE, 28(5), S81-S81.
• Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I & Skerry TM (2001) . Blood, 98(13), 3534-3540.
• Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Russell RGG & Croucher PI (2000) . British Journal of Haematology, 111(1), 283-286.
• Shipman CM, Holen I, Lippitt JM, Vandenberghe E & Croucher PI (2000) Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. BLOOD, 96(11), 360A-360A.
• Croucher PI, Shipman CM, Perry MJ, Lippitt J, Asosingh K, van Beek EJR, Van Camp B, Russell GG, Dunstan C & Vanderkerken K (2000) Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.. BLOOD, 96(11), 761A-761A.
• Shipman CM, Holen I, Lippitt JM, Edwards T & Croucher PI (2000) Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. JOURNAL OF BONE AND MINERAL RESEARCH, 15(6), 1217-1217.
• Harrop R, Blount DG, Khan N, Soyombo M, Moyce L, Drayson MT, Down J, Lawson MA, O’Connor D, Nimmo R , Lad Y et al () . Molecular Cancer Therapeutics.
• Rehman I, Evans CA, Glen A, Cross SS, Eaton CL, Down J, Pesce G, Phillips JT, Ow SY, Thalmann GN , Wright PC et al () . PLoS ONE, 7(5).
• Crawford A, Frazer A, Lippitt JM, Buttle DJ & Smith T () . Rheumatology, 45(12), 1529-1533.
• Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC & Eaton CL () . Journal of Bone and Mineral Research, 19(10), 1712-1721.
• Croucher PI, De Raeve H, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B & Vanderkerken K () . Journal of Bone and Mineral Research, 18(3), 482-492.

Conference proceedings papers

• Crabb SJ, Hussain SA, Oughton JB, Swain J, Cairns DA, Collinson M, Ainsworth G, McCready D, Griffin J, Heath P , Quayle L et al (2024) Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
• Griffin J, Down J, Quayle L, Heath P & Catto J (2023) Pathology Against the Clock: Verification of Gene Expression Subtyping for the GUSTO Clinical Trial. JOURNAL OF PATHOLOGY, Vol. 261(SUPPL1) (pp S49-S49)
• Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
• Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) . Experimental Hematology, Vol. 64(Suppl) (pp S74-S75). Los Angeles, USA, 23 August 2018 - 26 August 2018.
• Jiang Y, Down J, Raffles S, Jenkins E, Ferretti L, Bunce C, Drayson M, Lawson M & Khanim F (2018) TARGETING FREE LIGHT CHAIN (FLC) SECRETION AND THE UNFOLDED PROTEIN RESPONSE IN MYELOMA CELLS USING VAN, A COMBINATION OF REPURPOSED DRUGS. EXPERIMENTAL HEMATOLOGY, Vol. 64 (pp S75-S75)
• Pesce* G, Glen A, Lippitt J, Fowles A, Rehman I & Eaton CL (2011) . Bone, Vol. 48(1) (pp S46-S47)
• Cross NA, Papageorgiou M, Lippitt J, Nyambo R, Hamdy FC & Eaton CL (2007) Bone marrow stromal cell-derived insulin-like growth factor (IGF) II enhances growth and survival of prostate cancer cells and potentiates androgen action. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A94-A94)
• Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
• Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
• Cross SS, Hollingbury FE, Lippitt JM, Evans CA, Balasubramanian SP, Reed MWR, Handy FC & Winder SJ (2005) Loss of intercellular expression of beta-dystroglycan is a common event in breast cancer. JOURNAL OF PATHOLOGY, Vol. 205 (pp 8-8)
• Cross SS, Hollingbury FE, Lippitt JM, Feeley KM, Azzouzi AR, Winder SJ & Hamdy FC (2005) Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation. JOURNAL OF PATHOLOGY, Vol. 205 (pp 15-15)
• Cross SS, Hollingbury FE, Lippitt JM, Catto JW, Hamdy EC & Winder SJ (2005) beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6)
• Papageorgiou M, Lippitt J, Nyambo R, Cross N, Hamdy FC & Eaton CL (2005) Human bone marrow stromal cell derived IGF signaling enhances PSA production as well as proliferation/survival of androgen sensitive prostate cancer cells in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan CR, Carding SR & Morgan GJ (2004) T-cell-mediated colitis and bone destruction in a murine model of autoimmunity are both driven by RANK/RANK LIGAND interactions and modulated by recombinant Fc-OPG. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 125 (pp 67-67)
• Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
• Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Lippitt JM, Child JA, Dunstan C, Carding SR & Morgan GM (2003) T cell mediated colitis and bone destruction are driven by RANK/RANK LIGAND interactions and can be modulated by recombinant Fc-OPG.. BLOOD, Vol. 102(11) (pp 528A-528A)
• Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376)
• Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17(7) (pp 1339-1339)
• Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)

Preprints

• Jiang Y, Down JM, Maynard S, Jenkins S, Ferritti L, Beke F, Al-Hazmi B, Southam AD, Kvist J, Mirbahai L , Besse L et al (2023) , Research Square Platform LLC.
• Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E , Fraser WD et al () , Cold Spring Harbor Laboratory.